IP Library Granted Patent US 8,361,305
Granted Patent B2
US 8,361,305 · App. 12/840,590 · Granted Jan 29, 2013

Method and device for analyzing lipid component contained in serum

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,361,305
App. No.
12/840,590
Granted
Jan 29, 2013
Kind
B2
Abstract

To provide a method of analyzing a lipid component in serum which comprises: a first total acid concentration measurement step of electrochemically measuring the total acid concentration in a serum-containing analyte solution in the presence of a water-soluble quinone derivative; a fatty acid production step of allowing a lipid component in the serum to react with one or more kinds of enzymes which specifically act on the lipid component to produce a fatty acid; a second total acid concentration measurement step of electrochemically measuring the total acid concentration in the serum-containing analyte solution in the presence of the water-soluble quinone derivative; and a lipid component concentration calculation step of calculating the serum concentration of the lipid component based on the total acid concentration measured in the first total acid concentration measurement step and the total acid concentration measured in the second total acid measurement step.

Claims (14)

1. A method of analyzing a lipid component in serum comprising:

a first total acid concentration measurement of electrochemically measuring the total acid concentration in a serum-containing analyte solution;

a fatty acid production allowing a lipid component in the serum to react with one or more kinds of enzymes which specifically act on the lipid component to produce a fatty acid after the first total acid concentration measurement;

a second total acid concentration measurement electrochemically measuring the total acid concentration in the serum-containing analyte solution after the fatty acid production; and

a lipid component concentration calculation calculating the serum concentration of the lipid component based on the total acid concentration measured in the first total acid concentration measurement and the total acid concentration measured in the second total acid measurement, wherein the first total acid concentration measurement, the fatty acid production, and the second total acid concentration measurement are all conducted in the presence of a water-soluble quinone derivative in the presence of a water solvent in a same reaction cell.

2. The method according to claim 1 , wherein the electrochemical measurement in the presence of the water-soluble quinone derivative, which is conducted in the first total acid concentration measurement and in the second total acid concentration measurement, includes:

obtaining a voltammogram, and measuring the total acid concentration based on the amount of the difference between pre-reduction waves of the water-soluble quinone derivative in the voltammograms.

3. The method according to claim 1 , wherein the lipid component in the serum includes a cholesterol fatty acid ester, glycerin fatty acid ester, or a phospholipid.

4. The method according to claim 1 , wherein the water-soluble quinone derivative is a benzoquinone derivative.

5. The method according to claim 1 , wherein the water-soluble quinone derivative is dissolved into a water solvent to a concentration of 1 mM or higher.

6. The method according to claim 1 , wherein the water-soluble quinone derivative has a redox potential in the range of −400mV to 1,000 mV.

7. The method according to claim 1 , wherein the water-soluble quinone derivative generates a pre-reduction wave in a voltammogram.

8. The method according to claim 1 , wherein the water-soluble quinone derivative is 2,3-dimethoxy-5-methyl-p-benzoquinone.

9. The method according to claim 1 , wherein the water-soluble quinone derivative is 2,6-dimethyl-1,4-benzoquinone.

Assignments (6)
CHANGE OF NAME Recorded Jun 29, 2018
From: PANASONIC HEALTHCARE HOLDINGS CO., LTD.
To: PHC HOLDINGS CORPORATION
Reel/Frame 046459/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2014
From: PANASONIC CORPORATION
To: PHC HOLDINGS CO., LTD.
Reel/Frame 032785/0498 →
CHANGE OF NAME Recorded Apr 29, 2014
From: PHC HOLDINGS CO., LTD.
To: PANASONIC HEALTHCARE HOLDINGS CO., LTD.
Reel/Frame 032785/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2014
From: PANASONIC HEALTHCARE CO., LTD.
To: PANASONIC CORPORATION
Reel/Frame 032480/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2014
From: PANASONIC CORPORATION
To: PANASONIC HEALTHCARE CO., LTD.
Reel/Frame 032360/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2011
From: IKEDA, JUNKO; MACHIDA, KUNIHIKO; KOJIMA, SHINKI
To: PANASONIC CORPORATION
Reel/Frame 025749/0853 →